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INTRODUCTION 
Immune system is a host defense system comprising 
many biological structure and processes within an or-
ganism that protects the body against diseases, while 
simultaneously maintaining self-tolerance. The basic 
function of immune system is to protect against foreign 
pathogens and infectious agents. This is achieved either 
through innate or natural immunological mechanisms 
which essentially serve as a short term first line de-
fense or through adaptive mechanisms which are high-
ly specific, complex, and marked by diversity and 
memory [1]. Modulation of immune responses to alle-
viate the diseases has been of more interest for many 
years [2]. The term immunomodulators means regula-
tion of the immune system by suppression and stimula-
tion of the cells and organs of the immune system [3]. 
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Immunostimulation implies stimulation of nonspecific 
system i.e. stimulation of function and efficacy of mac-
rophages, granulocytes, T-lymphocytes and comple-
ment natural killer cells. There is need to stimulate im-
mune system in conditions of immune deficiency and 
variety of disease conditions (e.g., the treatment of 
AIDS, bacterial infections) or suppress it in case of nor-
mal or excessive immune function (e.g., the treatment 
of graft rejection, hypersensitivity reactions, autoim-
mune disease) [4]. Immunostimulation and immuno-
suppression both need to be tackled in order to regu-
late the normal immunological functioning. An im-
munomodulatory therapy is now being recognized as 
an alternative to conventional chemotherapy for a vari-
ety of disease conditions, involving impaired immune 
response of the host [5].  Due to wide range of effector 
mechanism possessed by various groups of immune 
cells and its ability to exert effects with exquisite speci-
ficity, immune system provide a good target in cancer 
therapy. Currently, there is a growth in diseases espe-
cially infectious diseases that requires efficient body 
defense mechanisms to control them through the pro-
cess of immunomodulation [6]. 
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Presently, focus on plant research has been intensified 
all over the world and a large amount of evidence has 
been collected to show immense potential of medicinal 
plants used in various traditional systems. In Indian 
system of medicine, many herbal drugs have been ad-
vocated for various types of diseases. A large number 
of plants and their isolated constituents have been 
known to possess immunomodulatory activity [7].  Di-
osgenin (C27 H42 O3) is a steroid saponin mainly pre-
sent in plants like Fenugreek (Trigonella foenum-
graecum) and other species of Dioscorea. It is also con-
sidered as the active constituent in the plant extract. 
Some of the therapeutic uses of Diosgenin include as 
an antioxidant, anticancer, anti-inflammatory, antihy-
perlipidemic etc. [8]. The beneficial effect of Diosgenin 
in immunomodulatory activity is attributed due to sap-
onin glycosides. Therefore, the aim of present study 
was to assess immunomodulatory effect of Diosgenin. 
MATERIALS AND METHODS 
Study design: An experimental animal based study 
Ethical approval: The experimental protocol was ap-
proved by the Institutional Animal Ethics Committee 
(COPH/IAEC/PG/02/2018). 
Study location: Dr.V.V.P. Foundation’s College of Phar-
macy, Ahmednagar. 
Study duration: 21 days 
Animals: The healthy albino wistar rats of either sex, 
weighing between 150-250 g were taken for the study. 
They were housed under standard environmental con-
ditions of temperature (23±2°c) humidity (55±5%) and 
12h light and 12h dark cycles. The animals were fed 
with standard pellet diet and water ad libitum.  
Sample size: Forty eight rats were used (in each group 
n=6) 
Drug and chemicals: Diosgenin was procured from Yar-
row Chem Products, Mumbai. Cyclophosphamide was 
procured as a marketed product “Cyclocel” of Celon 
Laboratories Ltd. Hyderabad. Colloidal carbon (Pelikan 
fount Indian ink, Hannovar, Germany) all other chemi-
cals were of analytical grade and purchased commer-
cially. Water used was double distilled throughout the 
study. 
Experimental protocol 
Dose selection of drug: Studies assessing steroidal sap-
onins for toxicity have shown that they did not show 
any sign of toxicity up to oral dose of 562.5 mg/kg. 
Therefore in the present study the dose of Diosgenin 
50, 100 and 150 mg/kg has been fixed. They were given 
by oral route using oral gavage [9]. 
Preparation of drug suspension: Diosgenin suspension 
was prepared in 0.5% w/v carboxymethylcellulose 
(CMC) in distilled water prior to oral administration to 
animals [12]. 
Preparation of SRBC suspension 
The blood was collected from a healthy sheep from the 
local slaughter house in sterile Alsevere’s solution in 
1:1 proportion of Alsevere’s solution (freshly pre-
pared) . It was preserved at a temperature of 2-8°C. On 
the day of immunization, the blood sample was centri-
fuged at 2000 rpm for 10 min and then washed three 
times with 0.9% sodium chloride solution. The SRBC 
(20% v/v) suspension was then prepared in 0.9% sodi-
um chloride solution [10].  
Preparation of Alsever’s solution: Formula of Alsever’s 
Solution is Citric acid 0.055g, Sodium citrate 0.8g, Glu-
cose 2.05g, Sodium chloride 0.42g, Distilled water to 
make volume up to 100 ml. The solution was stored in 
refrigerator [11].  
Preparation of Carbon ink suspension: Pelikan fount, 
Germany, ink was diluted eight times with saline and 
used for carbon clearance test in a volume of 1ml/100 
g [12]. 
Methods 
Immunomodulatory activity was evaluated using fol-
lowing models of specific (humoral, cellular) and non-
specific immunity. 
Assessment of humoral immune response to SRBC 
Haemagglutination Antibody (HA) titer [12] : The ani-
mals were divided into eight groups consisting of six 
animals each.  
Group I (Normal control) received distilled water (1ml/
kg, p.o.) for 21 days.  
Group II (Negative control) received Cyclophosphamide 
(100 mg/kg, p.o.) on 9th and 16th day as a single dose.  
Group III, IV and V received Diosgenin (50, 100, 150 
mg/kg, p.o.) respectively for 21 days. Immunosup-
pressed animals in Group VI, VII, VIII received Diosgenin 
(50, 100, 150 mg/kg, p.o.) for 21 days plus Cyclophos-
phamide (100 mg/kg, p.o.) on 9th and 16th day as a 
single dose.  
On 7th and 14th day, all the groups (i.e. Group I to VIII) 
were immunized and challenged respectively, with 
SRBCs in normal saline (0.1ml of 20% SRBCs, i.p.) blood 
was withdrawn on 14th and 21st day from retro-orbital 
plexus under mild ether anaesthesia from all antigeni-
cally sensitised and challenged rat respectively. Blood 
was centrifuged to obtain serum, normal saline was 
used as a diluent and SRBCs count was adjusted to 
(0.1% of SRBCs). Each well of a microtiter plate was 
filled initially with 20 μl of saline and 20 μl of serum 
was mixed in the first well of microtiter plate. Subse-
quently the 20 μl diluted serum was removed from first 
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well and added to the next well to get twofold dilutions 
of the antibodies present in the serum. Further twofold 
dilutions of this diluted serum were similarly carried 
out till the last well of the second row (24th well), so 
that the antibody concentration of any of the dilutions 
is half of the previous dilution. 20 μl SRBC (0.1% of 
SRBCs) were added to each of these dilutions and the 
plates were incubated at 37°C for one hour and then 
observed for haemagglutination. The highest dilution 
giving haemagglutination was taken as the antibody 
titer. The antibody titer were expressed in the graded 
manner, the minimum dilution (1/2) being ranked as 1, 
and mean ranks of different groups were compared for 
statistical significance. Antibody titer obtained on 14th 
day after immunization (on 7th day) and on 21st day 
after challenge (on 14th day) with SRBCs was measured 
as primary and secondary humoral immune response 
respectively. 
Assessment of cellular immune response induced by 
SRBC 
Delayed type hypersensitivity (DTH) response [13] 
The drug treatment was exactly the same as described 
for HA titer. On 14th day of the study, all the groups I 
to VIII were immunized with SRBCs (0.1ml of 20% SRBC, 
i.p.) in normal saline. On day 21st all animals from all 
the groups were challenged with 0.03 ml of 20% SRBCs 
in subplantar region of right hind paw and normal sa-
line in left hind paw in same volume. Foot pad oedema 
in rat was used for detection of cellular immune re-
sponse. Foot pad reaction was assessed after 24 hr. on 
22nd day, in terms of increase in the thickness of foot-
pad as a result of hypersensitivity reaction due to oede-
ma, the paw volume of the right hind footpad was 
measured by digital plethysmometer. The footpad re-
action was expressed as the difference in the volume 
(ml) between the right foot pad injected with SRBC and 
the left footpad injected with normal saline. 
Assessment of nonspecific immune response: Carbon 
clearance test [12, 14] 
The animals were divided into four groups consisting of 
six animals each.  
Group I (Normal control) received distilled water (1ml/
kg, p.o.) for 14 days.  
Group II, III, and IV received Diosgenin (50, 100, 150 
mg/kg, p.o.) respectively for 14 days. On 14th day, 3 
hours after the last dose all the animals of each group 
were given colloidal carbon intravenously in a volume 
of 1 ml/100 g. Blood samples were then collected (25 
µl) from retro orbital plexus at 0 and 15 minutes  after 
injection of colloidal carbon ink and mixed in 0.1% sodi-
um carbonate solution (3ml). The optical density was 
measured spectrophotometrically at 650 nm. The phag-
ocytic index (K) was calculated using the formula: 
                K =            (In OD1 – In OD2) 
                                         (t2 – t1) 
Where, OD1 and OD2 are the optical densities at time 
t1 and t2 respectively. 
Statistical Analysis: All the results were expressed as 
Mean±Standard Error (SEM). Data were analyzed using 
one-way analysis of variance (ANOVA) followed by Tuk-
ey-Kramer multiple comparison test. Value of P less 
than 5% (P<0.05) was considered statistically significant 
RESULTS 
1. Effect of Diosgenin on Haemagglutination antibody 
(HA) titer 
Effect of Diosgenin on primary and secondary antibody 
titer is shown in [Table 1]. Primary antibody titer on 
14th day negative control (Cyclophosphamide treated, 
100 mg/kg, p.o) group had shown significant decrease 
(# #p< 0.01) in primary antibody titer when compared 
with normal control. In Diosgenin-treated (50, 100 and 
150 mg/kg, p.o.) groups with normal immune status, 
showed significant rise (# #p<0.01) in primary antibody 
titer when compared with normal control. In immuno-
suppressed groups, where immunity was suppressed 
by administration of Cyclophosphamide on day nine, 
Diosgenin (50, 100 and 150 mg/kg, p.o.) administration 
produced a significant rise (** p< 0.01) in primary anti-
body titer when compared with negative control.  
Secondary antibody titer on 21st day negative control 
(Cyclophosphamide treated, 100 mg/kg, p.o.) group 
had shown significant decrease (##p<0.01) in second-
ary antibody titer when compared with normal control. 
In Diosgenin-treated (50, 100 and 150 mg/kg, p.o.) 
groups with normal immune status, showed significant 
rise (##p<0.01) in secondary antibody titer when com-
pared with normal control. In immunosuppressed 
groups, where immunity was suppressed by admin-
istration of Cyclophosphamide on day sixteenth, Dios-
genin (50, 100 and 150 mg/kg, p.o.) administration pro-
duced a significant rise (** p< 0.01) in secondary anti-
body titer when compared with negative control. 
2. Effect of Diosgenin on delayed type hypersensitivity 
response 
The Effect of Diosgenin on SRBC induced DTH response 
is shown in [Table 2]. On twenty-first day negative con-
trol (Cyclophosphamide treated, 100 mg/kg, p.o.) 
group showed significant decrease (##p< 0.01) in the 
mean difference of paw volume when compared with 
normal control. In the all groups of rat with normal 
immune status, treated with Diosgenin (50, 100, 150 
mg/kg, p.o.) showed significant potentiated (##p< 0.01) 
DTH response in terms of increase in the mean differ-
ence of paw volume when compared with normal con-
trol. In the all groups of rat treated with Cyclophospha-
mide i.e. an immunosuppressed groups, with Diosgenin 
(50,100,150 mg/kg, p.o.) showed significant potentiat-
ed (** p< 0.01)  DTH response in terms of increase in 
the mean difference of paw volume when compared 
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Table 1. Effect of Diosgenin treatment on primary and secondary antibody titer  
 
The values are expressed as (Mean ± S.E.M.), n=6, comparison were made as follows, 
##p<0.01, when negative control, normal immune status  
(i.e. Diosgenin-50, 100, 150 mg/kg) treated groups were compared with normal control. 
 **p<0.01, when immunosuppressed drug (Diosgenin-50, 100, 150 mg/kg + Cyp.)  
treated groups were compared with negative control.  
Statistically analyzed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparison 
test.  
T-50 = Diosgenin treated group (50 mg/kg) 
T-100 = Diosgenin treated group (100 mg/kg) 
T-150 = Diosgenin treated group (150 mg/kg) 
zSr. No. Treatment 
  
primary antibody titer 
(unit/ml) 
secondary antibody  titer       
(unit/ml) 
1 Normal control 4.08 ± 0.060 5.65 ± 0.022 
2 Negative control   3.48 ± 0.135# # 4.65 ± 0.030# # 
3 Diosgenin (T-50)   5.18 ± 0.060# # 8.11 ± 0.096# # 
4 Diosgenin (T-100)    6.16 ± 0.066# #  8.22 ± 0.022# # 
5 Diosgenin (T-150)   7.18 ± 0.060# # 8.65 ± 0.025# # 
6 Diosgenin (T-50) + Cyp.   5.26 ± 0.053 ** 7.19 ± 0.092 ** 
7 Diosgenin (T-100) + Cyp.   6.11 ± 0.099 ** 7.31 ±0.023 ** 
8 Diosgenin (T-150) + Cyp.   6.82 ± 0.018 ** 7.63 ±0.030 ** 






















Mean difference of paw volume in ml 
1 Normal control 0.22 ± 0.0106 
2 Negative control 0.301 ± 0.0101# # 
3 Diosgenin (T-50) 0.821 ± 0.0107# # 
4 Diosgenin (T-100) 0.905 ± 0.0117# # 
5 Diosgenin (T-150) 0.921 ± 0.008# # 
6 Diosgenin (T-50) + Cyp. 0.508 ± 0.009 ** 
7 Diosgenin (T-100) + Cyp. 0.643 ± 0.013 ** 
8 Diosgenin (T-150) + Cyp. 0.721 ± 0.011 ** 
The values are expressed as (Mean ± S.E.M.), n=6, comparison were made as follows, 
#p<0.01, when negative control, normal immune status (i.e. Diosgenin-50, 100 and 150 mg/kg) treated groups were 
compared with normal control. **p<0.01, when immunosuppressed drug (Diosgenin-50, 100, 150 mg/kg + Cyp.) 
treated groups were compared with negative control. Statistically analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey-Kramer multiple comparison test. 
Sr. No. Treatment Phagocytic Index 
1 Normal Control 0.027 ± 0.00096 
2 Diosgenin (T-50) 0.0165 ± 0.00088 ** 
3 Diosgenin (T-100) 0.0453 ± 0.00098 ** 
4 Diosgenin (T-150) 0.0748 ± 0.0012 ** 
Table 3. Effect of Diosgenin treatment on reticuloendothelial system by carbon clearance test 
The values are expressed as (Mean ± S.E.M), n=6, comparison were made as follows, 
** p<0.01, when all test drug (Diosgenin-50, 100 and 150 mg/kg) treated groups were compared with normal con-
trol. Statistically analyzed by one-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple compari-
son test. 
Int. j. clin. biomed. res. 2018;4(3):70-75. 
 74 
 
with negative control. Highlighted delayed type hyper-
sensitivity reaction suggests the activation of cellular 
immune system.  
Diosgenin treatment on the reticuloendothelial system 
by carbon clearance test is shown in [Table 3]. The 
phagocytic activity of the reticuloendothelial system is 
generally measured by the rate of removal of carbon 
particles from the blood stream. In carbon clearance 
test, the phagocytic index of Diosgenin-treated (50, 100 
and 150 mg/kg, p.o.) groups showed significant in-
creased (** p< 0.01)  in phagocytic index when com-
pared with normal control. This indicates stimulation of 
the reticuloendothelial system. 
DISCUSSION 
Immunomodulation is a procedure which can regulate 
the immune system of on organism by interfering with 
its function. Modulation of the immune system by stim-
ulation or suppression helps to maintain a disease-free 
state within an individual. Therefore, Immunomodula-
tors have been used worldwide to control disease con-
ditions. The study explored the immunomodulatory 
activity of Diosgenin by evaluating its effect on Hae-
magglutination antibody (HA) titer, DTH reactions, and 
on Phagocytic capacity of the reticuloendothelial sys-
tem. 
A haemagglutination test was performed to determine 
the effect of Diosgenin on humoral immunity. The hu-
moral immunity is mediated by B lymphocytes which 
involves interaction of B cells with the antigen and their 
subsequent proliferation and differentiation into plas-
ma cells which synthesize and secrete specific proteins 
called antibodies. Antibody functions as the effector of 
the humoral response by binding to antigen and neu-
tralizing it or facilitating its elimination [15]. To evalu-
ate the effect of Diosgenin on humoral response, its 
influence was tested by using SRBC’s as antigen in HA 
titer. Cyclophosphamide showed significant inhibition 
in antibody titer response as it suppresses B lympho-
cytes proliferation while, Diosgenin counteract the sup-
pression of both primary and secondary humoral re-
sponses induced by Cyclophosphamide. The results 
from this study demonstrated that Diosgenin stimulate 
the production of antibodies in an immunocompro-
mised animal.  
The DTH reaction is type IV delayed or Cell mediated 
hypersensitivity reactions, results from the interactions 
of sensitized T cells with a specific antigen [16]. The 
resulting cell mediated immune response is mediated 
by either direct cytotoxicity or by the release of lym-
phokines which causes activation and accumulation of 
macrophages, increases vascular permeability, induces 
vasodilation and produces inflammation [4]. This re-
sults in the net increase in the thickness of the foot pad 
in previously immunized animals. In this study, the in-
crease in footpad thickness of the rat that was subject-
ed to Diosgenin treatment could be attributed to the 
ability of the Diosgenin to activate lymphocytes and 
enhancement in the production of antibodies in the 
previously immunosuppressed animal, responsible for 
increasing cell-mediated immunity.  
Diosgenin showed stimulatory effect on the phagocytic 
capacity by exhibiting a clearance rate of carbon by the 
cells of the reticuloendothelial system (RES). The role of 
phagocytosis is the removal of microorganisms, foreign 
bodies, dead or injured cells. The increase in the carbon 
clearance rate reflects the enhancement of the phago-
cytic function of mononuclear macrophage and non-
specific immunity [17].  
CONCLUSION 
Based on the findings from the study, Diosgenin 
showed immunostimulant effect on specific arms of 
immune system, the humoral and cell mediated im-
munity and nonspecifically activated the immune sys-
tem by the activation of reticuloendothelial system 
because of saponin glycoside. Thus, it can be concluded 
that Diosgenin has potential therapeutic value in immu-
nosuppression clinical conditions and useful to alleviate 
disease conditions.  
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